New US cholesterol targets offer India a reference, not a template

The American heart doctors have redrawn the map for cholesterol management, and India is now asking whether the new boundaries apply to its own terrain. In August 2026, the American College of Cardiology and American Heart Association released updated guidelines that lower LDL cholesterol targets for high-risk patients—pushing the threshold down to 55 mg/dL for those with established heart disease, compared to the previous standard of 70 mg/dL. The shift represents more than just tighter numbers. It marks a philosophical turn: away from percentage-based reductions and toward catching cardiovascular risk earlier, weighing a person's lifetime exposure to artery-damaging particles, and treating based on actual risk rather than a single lab reading.

But India's cardiologists are cautious. The timing of the American guideline coincided with troubling data from the ICMR-INDIAB study, a massive screening effort that examined 121,078 adults across 36 states and Union Territories. The findings were stark: 87.3 percent of the sample carried at least one lipid abnormality—abnormal cholesterol, triglycerides, or related blood fats. When researchers pulled detailed lipid profiles from every fifth participant, they found that low HDL cholesterol (the protective kind) was present in nearly 67 percent of the 23,665 adults studied. High LDL appeared in 49.4 percent. High triglycerides in 29.5 percent. The pattern held across urban and rural populations, though urban residents showed slightly higher rates, and women showed higher rates than men.

What made the data uncomfortable was not just the prevalence but the timing. Dyslipidaemia peaked among adults aged 30 to 39, a decade or more before such abnormalities typically emerge in Western populations. About 40 percent of those with lipid problems had none of the conventional warning signs—no diabetes, no high blood pressure, no obesity. That 40 percent, the researchers estimated, could represent roughly 354.7 million Indians walking around with abnormal lipids while appearing metabolically healthy on the surface. The question became urgent: Can a framework built for American patients, who develop heart disease later in life, be applied to a population where the disease arrives years earlier and often without the usual red flags?

Dr. V Mohan, a co-author of the ICMR-INDIAB study and chairman of Dr Mohan's Diabetes Specialities Centre, saw the American guideline not as a threat but as validation. India already operates its own risk-based framework through the Lipid Association of India, built around lifetime cardiovascular risk and factors beyond LDL cholesterol alone. The new American emphasis on early detection and lifetime risk exposure aligned with what Indian specialists were already doing. He resisted, however, the idea of applying the American targets uniformly. Not every heart disease patient needs an LDL below 55 mg/dL. The target depends on risk category and individual circumstances, not diagnosis alone.

Dr. Vithal D Bagi, a senior cardiologist at Apollo Hospitals in Bengaluru, pushed the argument further. Indians develop coronary artery disease roughly a decade earlier than Western populations, he noted, and Indian guidelines already emphasize non-HDL cholesterol and ApoB—a protein that marks how many artery-clogging particles circulate in the blood—more heavily than LDL-C alone. The American guideline treats these as secondary. Here lay a paradox: the new American thresholds of 70 and 55 mg/dL were not, in most cases, more aggressive than what Indian specialists already used. The Lipid Association of India already recommended below 50 mg/dL for very high-risk patients and below 30 mg/dL for extreme risk. In some respects, Indian practice had already moved ahead.

The real gap emerged elsewhere. The American guideline introduced PREVENT-ASCVD, a new risk calculator for adults aged 30 to 79 without established heart disease, replacing a formula that had been in use for over a decade. But that calculator was built from American population data. Dr. Bagi argued that it could not capture a disease pattern that shows up years earlier in Indians. He wanted risk scores built specifically for younger Indian adults, paired with earlier lifestyle intervention and lifetime risk assessment. Dr. Mohan took a more measured stance. No calculator could capture every factor behind lifetime cardiovascular risk, he said. The Indian framework increasingly folded in family history, subclinical atherosclerosis—early artery buildup that hasn't caused symptoms—non-HDL cholesterol, ApoB, and Lp(a), a genetically inherited particle linked to heart risk that diet and exercise barely touch.

The deeper issue was detection. The ICMR-INDIAB finding that 40 percent of people with dyslipidaemia had no diabetes, hypertension, or obesity meant that conventional risk calculators could miss them entirely. A person could appear healthy by standard measures and still carry abnormal lipids. For Dr. Mohan, this was a case for broader screening, not for abandoning risk calculators. For Dr. Bagi, it meant treating lipid targets with the same discipline usually reserved for blood pressure or blood sugar in diabetic patients. The lower the modifiable risk factors, the lower the cardiovascular risk.

What emerged from the debate was not a choice between adopting the American framework or rejecting it, but a recognition that India needed something different. The American guideline offered a useful reference point, a shift in thinking toward earlier detection and lifetime risk. But India's cardiovascular landscape was distinct. Risk built quietly, often in people who looked metabolically healthy. The harder task was not deciding which target to chase. It was finding that risk early enough to act on it—before the first heart attack revealed what had been building all along.